Jul

2009

Limerick BioPharma, Inc.: Series C $15M

Posted in I - Series C, Q - 3Q09, R - WEST, X - Immunology, X - Metabolism, X - Pain, XX - CA

Limerick BioPharma (San Francisco, CA) a clinical-stage biopharmaceutical company focused on the modulation of cellular pumps and other transporters, closed a $15M Series C financing. Participants include OVP Venture Partners, ARCH Venture Partners, Sevin Rosen Funds and Altitude Funds.

Jul

2009

Intrexon Corp.: Series C $10M

Posted in I - Series C, Q - 2Q09, R - SOUTH EAST, X - Immunology, X - Oncology, X - Therapeutic Platform, XX - VA

Intrexon (Blacksburg, VA) a clinical-stage biopharmaceutical company focused on modular inducible cancer immunotherapeutics, closed a $10M Series C bring the total round financing to date of $35M. Participants include New River Management.

Jul

2009

Aileron Therapeutics, Inc.: Series D $40M

Posted in I - Series D, Q - 2Q09, R - NORTH EAST, X - Immunology, X - Inflammation, X - Metabolism, X - Oncology, XX - MA

Aileron Therapeutics (Cambridge, MA) a pre-clinical large molecule biopharmaceutical company focused on oncology, inflammation and metabolic and infectious diseases, closed a $40M Series D financing. Participants include Excel Medical Ventures, SR One, Lilly Ventures, Roche Venture Fund, Apple Tree Partners and Novartis Venture Funds.

Jun

2009

Inimex Pharmaceuticals, Inc.: Series B $22M

Posted in I - Series B, Q - 2Q09, R - INTERNATIONAL, X - Immunology, X - Inflammation

Inimex Pharmaceuticals (Canada) a clinical-stage biopharmaceutical company focused on infectious diseases and inflammatory disorders, closed a $22M Series B financing. Participants include Morningside, Roche Venture Fund, Astellas Venture Management, Advantage Life Science Fund, BC Advantage Funds, BDC Venture Capital, British Columbia Discovery Fund, Canadian Medical Discovery Fund, and Working Opportunity Fund.

Jun

2009

XORI Corp.: Series A $3M*

Posted in I - Series A, Q - 2Q09, R - NORTH WEST, X - Antibody, X - Antiinfective, X - Immunology, X - Oncology, XX - WA

XORI (Seattle, WA) a development-stage company focused on a technology for the rapid discovery and development of therapeutic monoclonal antibodies for oncology, immune disorders and infectious disease, closed a $3M Series A financing. Participants include Alexandria Real Estate Equities, Amgen Ventures, ARCH Venture Partners, OVP Venture Partners, PPD, and WRF Capital.
*value was undisclosed

Jun

2009

Anaphore, Inc.: Series A $13M

Posted in I - Series A, Q - 2Q09, R - WEST, X - Atrimer, X - Immunology, X - Oncology

Anaphore (La Jolla, CA) is developing a class of protein therapeutics, Atrimers, to address immune-mediated disease and oncology, closed a $13M Series A bring the total round of financing to $38M. Participants include SR One, Merck Serono Ventures, 5AM Ventures, Apposite Capital and Versant Ventures.

Jun

2009

NovImmune, SA: Series C $54.8M

Posted in I - Series C, Q - 2Q09, R - INTERNATIONAL, X - Antibody, X - Diabetes, X - Immunology, X - Inflammation

NovImmune (Switzerland) a clinical-stage biopharmaceutical company focused on therapeutic monoclonal antibodies for inflammatory diseases and immune related disorders, closed a $54.8M series C financing. Participants include BZ Bank Aktiengesellschaft.

Mar

2009

NKT Therapeutics, Inc.: Series A $8M

Posted in I - Series A, Q - 1Q09, R - NORTH EAST, X - Antibody, X - Asthma, X - Immunology, XX - MA

NKT Therapeutics (Newton, MA) a pre-clinical stage therapeutic company focused on asthma, closed a $8M Series A financing. Participants include SV Life Sciences and MedImmune Ventures.

Mar

2009

Selecta Biosciences, Inc.: Series B $15.1M

Posted in I - Series B, Q - 1Q09, R - NORTH EAST, X - Immunology, X - Therapeutic Platform

Selecta Biosciences (Watertown, MA) a pre-clinical stage company focused on rational design of targeted immunomodulatory nanoparticles to induce or modify cellular and/or humoral immune responses for therapeutic and prophylactic indications, closed a $15.1M Series B financing. Participants include Polaris Venture Partners, Flagship Ventures and NanoDimension.

Jan

2009

Anaphore, Inc.: Series A $25M

Posted in I - Series A, Q - 1Q09, R - WEST, X - Atrimer, X - Immunology, X - Oncology, XX - CA

Anaphore (La Jolla, CA) is developing a class of protein therapeutics, Atrimers, to address immune-mediated disease and oncology, closed a $25M Series A financing. Participants include Apposite Capital, 5am Ventures and Versant Ventures.

Dec

2008

Argos Therapeutics, Inc.: Series C $35.2M

Posted in I - Series C, Q - 4Q08, R - SOUTH EAST, X - HIV, X - Immunology, X - Oncology

Argos Therapeutics (Research Triangle Park, NC) clinical-stage developer of personalized immunotherapies for cancer and HIV, closed a $35.2M Series C financing. Participants include TVM Capital, Mizuho Capital, Morningside Group, Japan Asia Investment Group, Lumira Capital, Forbion Capital Partners, CDP Capital, Intersouth Partners, Aurora Capital and GeneChem.

Dec

2008

Telormedix, SA: Series A $19M

Posted in I - Series A, Q - 3Q08, R - INTERNATIONAL, X - Immunology, X - Oncology

Telormedix (Switzerland) developer of immunotherapeutics for cancer, closed a $19M Series A financing. Participants include Aravis Ventures, Proquest Investments, BSI SA, Nextech Venture and Generali Insurance Group.

Dec

2008

Trillium Therapeutics, Inc.: Series C $12M

Posted in I - Series C, Q - 3Q08, R - INTERNATIONAL, X - Immunology

Trillium Therapeutics (Canada) early-stage company focused on the development of therapies for the treatment of immune-mediated disorders, closed a $12M Series C financing. Participants include VenGrowth Private Equity Partners, BDC Capital and Canadian Medical Discoveries Fund.

« Previous Entries Next Entries »

to top of page...